Alexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.
Alexander M. Lesokhin, MD
Advertisement
Articles by Alexander M. Lesokhin, MD
Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape for patients with multiple myeloma.
Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Lesokhin on the Current Treatment Landscape of MyelomaPublished: September 14th 2018 | Updated:
Dr. Lesokhin Discusses Exciting Advances in Multiple MyelomaPublished: July 14th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5